ストックスクリーナーアプリを入手
6.93
4.52%
0.30
アフターアワーズ：
6.94
0.01
+0.14%
Kyverna Therapeutics Inc (KYTX) 最新ニュース
What MACD signals say about Kyverna Therapeutics Inc.Analyst Upgrade & Weekly High Conviction Ideas - newser.com
How moving averages guide Kyverna Therapeutics Inc. tradingMarket Growth Summary & Verified Entry Point Detection - newser.com
Intraday pattern recognizer results for Kyverna Therapeutics Inc.Market Rally & Risk Managed Investment Strategies - newser.com
Kyverna Therapeutics Inc Stock Analysis and ForecastCash Flow Trends & Small Investment Trading Growth - earlytimes.in
Long term hold vs stop loss in Kyverna Therapeutics Inc.Market Performance Report & Growth Focused Investment Plans - newser.com
Historical volatility pattern of Kyverna Therapeutics Inc. visualized2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
Kyverna Therapeutics, Inc. Securities Lawsuit Investigation - Claim Depot
Wells Fargo Maintains Kyverna Therapeutics (KYTX) Overweight Recommendation - Nasdaq
Kyverna Therapeutics stock price target raised to $27 at Wells Fargo - Investing.com
Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight - GlobeNewswire Inc.
What drives Kyverna Therapeutics Inc stock priceLow Beta Stocks & Join a Community of Smart Investors - earlytimes.in
What’s next for Kyverna Therapeutics Inc. stock priceGold Moves & Detailed Earnings Play Alerts - newser.com
Why retail investors favor Kyverna Therapeutics Inc. stockJuly 2025 WrapUp & Advanced Swing Trade Entry Plans - newser.com
Is Kyverna Therapeutics Inc. forming a bottoming base2025 Major Catalysts & Consistent Profit Alerts - newser.com
Live market analysis of Kyverna Therapeutics Inc.July 2025 Movers & Real-Time Volume Analysis - newser.com
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Should you hold or exit Kyverna Therapeutics Inc. nowWeekly Market Summary & Momentum Based Trading Ideas - newser.com
Institutional scanner results for Kyverna Therapeutics Inc.2025 Year in Review & Weekly Watchlist for Consistent Profits - newser.com
What analysts say about Kyverna Therapeutics Inc stockGlobal Market Influence & Free Dynamic Capital Growth - earlytimes.in
Kyverna Therapeutics: KYV-101 Heads Toward Phase 3 In MG; Q4 Data In Sight - RTTNews
Goldman Sachs Group Inc. Reduces Stock Position in Kyverna Therapeutics, Inc. $KYTX - Defense World
Kyverna Therapeutics Announces Board Member Resignation - MSN
Kyverna Therapeutics announces board resignation and committee changes - Investing.com India
Kyverna Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Kyverna Therapeutics announces board resignation and committee changes By Investing.com - Investing.com Nigeria
Kyverna Therapeutics stock rating reiterated at Buy by H.C. Wainwright By Investing.com - Investing.com Nigeria
Kyverna’s KYV-101 shows promising results in multiple sclerosis trials By Investing.com - Investing.com Nigeria
Kyverna’s KYV-101 shows promising results in multiple sclerosis trials - Investing.com
Kyverna Therapeutics announces updated data from Phase 1 IITs of KYV-101 - TipRanks
Kyverna Therapeutics Reports Promising Phase 1 Data for KYV-101 in Progressive Multiple Sclerosis, Highlighting CNS Penetration and Clinical Activity - Quiver Quantitative
Kyverna Therapeutics Highlights Potential of KYV-101 in - GlobeNewswire
Breakthrough MS Treatment: Kyverna's CAR T-Cell Therapy Shows CNS Penetration and Disability Improvement - Stock Titan
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS - Sahm
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Block Trades: What is Kyverna Therapeutics Incs book value per share2025 Market Outlook & Real-Time Stock Price Movement Reports - خودرو بانک
Will Kyverna Therapeutics (NASDAQ:KYTX) Spend Its Cash Wisely? - 富途牛牛
1.11%
大文字化:
|
ボリューム (24 時間):